Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,529 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and In Situ Virus Gene Therapy in Metastatic Triple-Negative Breast Cancer.
Sun K, Xu Y, Zhang L, Niravath P, Darcourt J, Patel T, Teh BS, Farach AM, Guerrero C, Mathur S, Sultenfuss MA, Gupta N, Schwartz MR, Haley SL, Nair S, Li X, Nguyen TTA, Butner JD, Ensor J, Mejia JA, Mei Z, Butler EB, Chen SH, Bernicker EH, Chang JC. Sun K, et al. Among authors: mei z. Clin Cancer Res. 2022 Oct 14;28(20):4392-4401. doi: 10.1158/1078-0432.CCR-22-0622. Clin Cancer Res. 2022. PMID: 35877117 Free PMC article. Clinical Trial.
A Phase 2 Study of In Situ Oncolytic Virus Therapy and Stereotactic Body Radiation Therapy Followed by Pembrolizumab in Metastatic Non-Small Cell Lung Cancer.
Guan J, Sun K, Guerrero CA, Zheng J, Xu Y, Mathur S, Teh BS, Farach A, Zhang J, Butler E, Pan PY, Zsigmond E, Mei Z, Mejia J, Chen SH, Chang JC, Bernicker EH. Guan J, et al. Among authors: mei z. Int J Radiat Oncol Biol Phys. 2024 Apr 1;118(5):1531-1540. doi: 10.1016/j.ijrobp.2023.08.044. Epub 2023 Aug 24. Int J Radiat Oncol Biol Phys. 2024. PMID: 37625523 Clinical Trial.
Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors.
Lin FY, Stuckert A, Tat C, White M, Ruggieri L, Zhang H, Mehta B, Lapteva N, Mei Z, Major A, Thakkar S, Shum T, Parikh K, Wu MF, Lindsay HB, Scherer L, Shekar M, Baxter P, Wang T, Grilley B, Moeller K, Hicks J, Roy A, Anastas J, Malbari F, Aldave G, Chintagumpala M, Blaney S, Parsons DW, Brenner MK, Heslop HE, Rooney CM, Omer B. Lin FY, et al. Among authors: mei z. J Clin Oncol. 2024 Aug 10;42(23):2769-2779. doi: 10.1200/JCO.23.02019. Epub 2024 May 21. J Clin Oncol. 2024. PMID: 38771986 Free PMC article. Clinical Trial.
Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma.
Ahmed N, Brawley VS, Hegde M, Robertson C, Ghazi A, Gerken C, Liu E, Dakhova O, Ashoori A, Corder A, Gray T, Wu MF, Liu H, Hicks J, Rainusso N, Dotti G, Mei Z, Grilley B, Gee A, Rooney CM, Brenner MK, Heslop HE, Wels WS, Wang LL, Anderson P, Gottschalk S. Ahmed N, et al. Among authors: mei z. J Clin Oncol. 2015 May 20;33(15):1688-96. doi: 10.1200/JCO.2014.58.0225. Epub 2015 Mar 23. J Clin Oncol. 2015. PMID: 25800760 Free PMC article. Clinical Trial.
Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes.
Ramos CA, Ballard B, Zhang H, Dakhova O, Gee AP, Mei Z, Bilgi M, Wu MF, Liu H, Grilley B, Bollard CM, Chang BH, Rooney CM, Brenner MK, Heslop HE, Dotti G, Savoldo B. Ramos CA, et al. Among authors: mei z. J Clin Invest. 2017 Sep 1;127(9):3462-3471. doi: 10.1172/JCI94306. Epub 2017 Aug 14. J Clin Invest. 2017. PMID: 28805662 Free PMC article. Clinical Trial.
Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study.
Cruz CR, Micklethwaite KP, Savoldo B, Ramos CA, Lam S, Ku S, Diouf O, Liu E, Barrett AJ, Ito S, Shpall EJ, Krance RA, Kamble RT, Carrum G, Hosing CM, Gee AP, Mei Z, Grilley BJ, Heslop HE, Rooney CM, Brenner MK, Bollard CM, Dotti G. Cruz CR, et al. Among authors: mei z. Blood. 2013 Oct 24;122(17):2965-73. doi: 10.1182/blood-2013-06-506741. Epub 2013 Sep 12. Blood. 2013. PMID: 24030379 Free PMC article. Clinical Trial.
CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma.
Heczey A, Louis CU, Savoldo B, Dakhova O, Durett A, Grilley B, Liu H, Wu MF, Mei Z, Gee A, Mehta B, Zhang H, Mahmood N, Tashiro H, Heslop HE, Dotti G, Rooney CM, Brenner MK. Heczey A, et al. Among authors: mei z. Mol Ther. 2017 Sep 6;25(9):2214-2224. doi: 10.1016/j.ymthe.2017.05.012. Epub 2017 Jun 9. Mol Ther. 2017. PMID: 28602436 Free PMC article.
Phase 1 clinical trial of adoptive immunotherapy using "off-the-shelf" activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia.
Boyiadzis M, Agha M, Redner RL, Sehgal A, Im A, Hou JZ, Farah R, Dorritie KA, Raptis A, Lim SH, Wang H, Lapteva N, Mei Z, Butterfield LH, Rooney CM, Whiteside TL. Boyiadzis M, et al. Among authors: mei z. Cytotherapy. 2017 Oct;19(10):1225-1232. doi: 10.1016/j.jcyt.2017.07.008. Epub 2017 Aug 30. Cytotherapy. 2017. PMID: 28864289 Clinical Trial.
Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma.
Rousseau RF, Haight AE, Hirschmann-Jax C, Yvon ES, Rill DR, Mei Z, Smith SC, Inman S, Cooper K, Alcoser P, Grilley B, Gee A, Popek E, Davidoff A, Bowman LC, Brenner MK, Strother D. Rousseau RF, et al. Among authors: mei z. Blood. 2003 Mar 1;101(5):1718-26. doi: 10.1182/blood-2002-08-2493. Epub 2002 Oct 24. Blood. 2003. PMID: 12406881 Free article. Clinical Trial.
1,529 results